NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial
Open Access
- 22 April 2023
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 33, 101145
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme United Kingdom
- Merck Sharp and Dohme United Kingdom
This publication has 44 references indexed in Scilit:
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after NephrectomyNew England Journal of Medicine, 2016
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialThe Lancet, 2016
- Consensus Statement from the International Radiosurgery Oncology Consortium for Kidney for Primary Renal Cell CarcinomaFuture Oncology, 2016
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor AntigenCancer Immunology Research, 2015
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 BlockadeCancer Research, 2014
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJournal of Clinical Investigation, 2014
- Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trialsAnnals of Oncology, 2010
- Surveillance following radical or partial nephrectomy for renal cell carcinomaCurrent Urology Reports, 2005
- Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent diseaseUrologic Clinics of North America, 2003
- Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell CarcinomaJournal of Clinical Oncology, 2002